Cannabis Mold Testing: Standards, Methods, and State Requirements

Executive Summary

Cannabis mold testing has emerged as one of the most contentious quality control issues in state-regulated markets, with inconsistent standards across jurisdictions creating patient safety concerns and operational headaches for cultivators. While all adult-use and medical cannabis states require some form of microbial testing before products reach dispensary shelves, the specific molds tested for, detection methods employed, and acceptable threshold levels vary dramatically from California to Massachusetts. The debate intensified in May 2026 when industry stakeholders questioned whether current testing protocols adequately protect immunocompromised patients who face serious health risks from inhaling mold-contaminated cannabis. At stake are billions of dollars in crop value annually, patient access to medicine, and the credibility of state regulatory frameworks that promised pharmaceutical-grade safety standards. This article examines the science of cannabis mold contamination, the evolution of state testing requirements, the economic impact of failed batches, and the ongoing regulatory debate over whether existing protocols meet the medical-grade standards many patients expect.

Why Cannabis Mold Testing Matters

Mold contamination in cannabis poses documented health risks to immunocompromised patients, affects approximately $400 million in annual crop failures across legal markets, and represents a critical gap between state regulations and pharmaceutical safety standards. The stakes are highest for medical cannabis patients undergoing chemotherapy, living with HIV/AIDS, or taking immunosuppressant medications following organ transplants. A 1988 case report published in the Journal of Clinical Microbiology documented a bone marrow transplant patient who developed fatal pulmonary aspergillosis after smoking cannabis contaminated with Aspergillus fumigatus. While such severe outcomes remain rare, pulmonary specialists have documented dozens of cases linking cannabis inhalation to fungal infections in vulnerable populations. The economic impact extends across the supply chain. Cultivators face total loss when batches fail microbial testing, with no remediation pathway in most states. A single failed harvest can represent $50,000 to $500,000 in lost revenue for small to mid-sized operators. Testing laboratories charge $200 to $400 per sample for comprehensive microbial panels, adding significant compliance costs. Dispensaries lose inventory and customer trust when recalls occur. According to data compiled by the Cannabis Regulators Association, microbial contamination accounted for approximately 35 percent of all product failures in 2025, surpassing pesticide violations. The regulatory credibility of state programs depends on delivering the safety promises made to voters and legislators. When California, Massachusetts, and other states legalized adult-use cannabis, proponents emphasized seed-to-sale tracking and mandatory testing as safeguards distinguishing legal products from black market alternatives. Inconsistent enforcement and inadequate testing protocols undermine that value proposition, potentially driving consumers back to untested sources.

The Science of Cannabis Mold Contamination

Cannabis plants are susceptible to fungal colonization throughout cultivation, harvest, drying, and storage, with Aspergillus, Penicillium, and Mucor species posing the greatest documented health risks.

How Mold Colonizes Cannabis

Fungal spores are ubiquitous in indoor and outdoor growing environments. Cannabis flowers provide an ideal substrate when environmental conditions favor mold growth: relative humidity above 60 percent, inadequate air circulation, and temperatures between 77°F and 86°F. The dense structure of cannabis buds traps moisture, creating microenvironments where mold can proliferate even when ambient conditions appear controlled. Aspergillus species are the most frequently detected and medically significant contaminants. Aspergillus fumigatus, A. flavus, and A. niger produce airborne spores that healthy individuals typically clear from their lungs without issue. Immunocompromised patients lack this defense, making invasive aspergillosis a life-threatening risk. Aspergillus flavus also produces aflatoxins, carcinogenic mycotoxins regulated separately in some state programs. Penicillium species commonly appear on improperly cured cannabis. While Penicillium contamination rarely causes invasive infections, it indicates poor post-harvest handling and can produce allergenic compounds. Mucor and Rhizopus species cause visible fuzzy growth and indicate severe moisture control failures. Botrytis cinerea, known as gray mold or bud rot, destroys crops in the field but is typically identified visually before harvest. Testing focuses on organisms that may colonize cannabis without obvious visual indicators.

Detection Methods and Their Limitations

State-mandated testing relies primarily on two methodologies: culture-based plating and quantitative polymerase chain reaction (qPCR). Culture-based methods involve plating cannabis samples on growth media and counting colony-forming units (CFUs) after incubation. This approach detects viable organisms and allows species identification. However, culture methods require 3 to 7 days for results, may miss slow-growing or fastidious organisms, and provide limited sensitivity for low-level contamination. qPCR detects fungal DNA, delivering results within hours and offering superior sensitivity. qPCR can identify specific species and quantify contamination levels. The limitation: qPCR detects DNA from both living and dead organisms, potentially flagging cannabis that underwent successful remediation or heat treatment. Some operators argue qPCR produces false positives, while patient advocates counter that any presence of pathogenic fungal DNA indicates unacceptable contamination. Mass spectrometry methods are emerging but not yet widely adopted in cannabis testing. These techniques can detect mycotoxins directly, providing functional safety data rather than simply counting organisms.

History and Evolution of Cannabis Mold Testing Requirements

Cannabis microbial testing evolved from non-existent in early medical programs to mandatory but inconsistent across modern adult-use states, driven by patient safety incidents and industry professionalization between 1996 and 2026.

1996-2010: The Unregulated Era

When California voters approved Proposition 215 in 1996, establishing the nation's first medical cannabis program, no testing requirements existed. Patients and caregivers grew cannabis without quality control oversight. Dispensaries operated in legal gray areas with no regulatory framework for product safety. This period saw scattered case reports of fungal infections linked to cannabis use, but systematic data collection was impossible. Colorado and other early medical states similarly lacked testing mandates through the 2000s. The cannabis industry operated more like farmers' markets than pharmaceutical supply chains.

2010-2014: First Testing Mandates Emerge

As medical cannabis programs matured and patient populations grew, pressure mounted for safety standards. In 2010, the City of Berkeley, California became one of the first jurisdictions to require microbial testing for dispensary products. The Berkeley ordinance mandated testing for total yeast and mold, E. coli, and Salmonella, setting action levels at 10,000 CFU/g for total yeast and mold. Colorado's Amendment 64, legalizing adult-use cannabis in 2012, included provisions for mandatory testing. The Colorado Department of Public Health and Environment developed rules requiring microbial testing by 2014, though initial standards focused primarily on E. coli and Salmonella rather than fungal pathogens.

2015-2018: The California Regulatory Model

California's transition from loosely regulated medical cannabis to comprehensive adult-use regulation under Proposition 64 (2016) created the most detailed microbial testing framework to date. The Bureau of Cannabis Control, working with the Department of Public Health, established testing requirements that took effect January 1, 2018. California's regulations required testing for specific Aspergillus species (A. fumigatus, A. flavus, A. niger, and A. terreus) with a zero-tolerance standard: any detection resulted in batch failure. The state also set limits for total yeast and mold, Shiga toxin-producing E. coli, and Salmonella. The California model influenced subsequent state programs. Massachusetts, Michigan, and Illinois adopted similar frameworks requiring specific pathogen testing rather than generic microbial counts.

2018-2020: The Remediation Debate

As testing came online, cultivators faced massive crop losses. Industry groups lobbied for remediation pathways, arguing that processes like ozone treatment, irradiation, or ethanol extraction could render contaminated cannabis safe for consumption. California initially prohibited remediation of failed batches, requiring destruction. In 2019, the state adopted emergency regulations allowing remediation through specific processes, followed by retesting. Oregon and Nevada developed similar frameworks. Massachusetts maintained its prohibition on remediating flower that failed microbial testing, though concentrates could be produced from failed flower. The remediation debate highlighted fundamental questions: Does killing mold organisms through irradiation eliminate health risks, or do dead spores and mycotoxins still pose dangers? Patient advocates argued that immunocompromised individuals should never consume products that initially failed testing, regardless of remediation.

2020-2026: Standardization Efforts and Ongoing Gaps

The Association of Official Agricultural Chemists (AOAC) International began developing standardized methods for cannabis microbial testing in 2020, aiming to create validated protocols comparable to food safety testing. AOAC Official Method 2020.04 for Aspergillus detection in cannabis was published in 2021, providing laboratories with a peer-reviewed methodology. Despite standardization efforts, significant interstate variation persists. As of May 2026, action levels for total yeast and mold range from 10,000 CFU/g in some states to 100,000 CFU/g in others. Some states test for specific Aspergillus species, while others rely only on total counts. Testing frequency varies: per-batch in some jurisdictions, statistical sampling in others. The lack of federal oversight perpetuates this fragmentation. The FDA regulates microbial contamination in food and pharmaceuticals through detailed guidance documents and enforcement actions. Cannabis remains a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), preventing FDA from establishing national standards even as state markets mature.

State-by-State Testing Requirements

Microbial testing mandates vary dramatically across legal cannabis states, with differences in target organisms, detection methods, action levels, and remediation policies creating a patchwork of safety standards.

California

California requires testing for Aspergillus fumigatus, A. flavus, A. niger, and A. terreus with zero tolerance (any detection fails). Total yeast and mold must not exceed 10,000 CFU/g. Testing also covers Shiga toxin-producing E. coli and Salmonella (both zero tolerance). The California Department of Cannabis Control allows remediation of failed batches through approved processes including ethanol extraction, with mandatory retesting. Testing occurs at licensed laboratories using validated methods. Regulations are codified in California Code of Regulations Title 16, Division 42.

Colorado

Colorado's Marijuana Enforcement Division requires testing for E. coli, Salmonella, and total yeast and mold. The action level for yeast and mold is 10,000 CFU/g for flower intended for inhalation. Unlike California, Colorado does not mandate species-specific Aspergillus testing. Remediation is permitted through processes that render products safe, with retesting required. Colorado uses culture-based methods as the primary testing approach.

Massachusetts

The Massachusetts Cannabis Control Commission requires testing for Aspergillus species (A. fumigatus, A. flavus, A. niger, A. terreus) with zero tolerance. Total yeast and mold limits are set at 10,000 CFU/g. E. coli and Salmonella are also tested with zero tolerance. Massachusetts prohibits remediation of flower that fails microbial testing; failed batches must be destroyed. Concentrates may be produced from failed flower if the extraction process is validated to eliminate contaminants. Regulations appear in 935 CMR 500.000.

Michigan

Michigan requires testing for Aspergillus species, E. coli, and Salmonella. The state uses qPCR methods for Aspergillus detection. Total aerobic bacteria and total yeast and mold are tested with action levels of 100,000 CFU/g and 10,000 CFU/g respectively. Michigan allows remediation through approved processes. The Marijuana Regulatory Agency oversees testing requirements under the Michigan Regulation and Taxation of Marihuana Act.

Illinois

Illinois mandates testing for Aspergillus (A. fumigatus, A. flavus, A. niger, A. terreus), E. coli, and Salmonella, all with zero tolerance. Total yeast and mold must not exceed 10,000 CFU/g. The Illinois Department of Agriculture prohibits sale of products that fail microbial testing but allows remediation through extraction or other approved processes with retesting. Testing occurs at licensed laboratories following standardized protocols.

Oregon

Oregon requires testing for E. coli and Salmonella but does not mandate species-specific Aspergillus testing. Total yeast and mold limits are set at 10,000 CFU/g. The Oregon Liquor and Cannabis Commission allows remediation of failed batches through processes including CO2 extraction and ethanol extraction. Oregon's less stringent requirements have drawn criticism from patient advocates.

Nevada

Nevada tests for Aspergillus species, E. coli, and Salmonella. Total yeast and mold action level is 10,000 CFU/g. The Nevada Cannabis Compliance Board permits remediation through approved methods. Testing must occur at independent licensed laboratories.

Washington

Washington requires testing for E. coli and Salmonella but does not mandate specific Aspergillus testing. Total yeast and mold limits are 10,000 CFU/g. The Washington State Liquor and Cannabis Board allows remediation. Washington's framework is considered less comprehensive than California or Massachusetts models.

New York

New York's adult-use program, launched in 2022, requires testing for Aspergillus species, E. coli, and Salmonella. The Office of Cannabis Management set total yeast and mold limits at 10,000 CFU/g. Remediation policies are still evolving as the market matures.

Ohio

Ohio's medical cannabis program requires testing for Aspergillus, E. coli, and Salmonella. Total yeast and mold action level is 10,000 CFU/g. The Ohio Board of Pharmacy oversees testing requirements. Remediation is permitted through approved processes.

Key Players in the Mold Testing Debate

The cannabis mold testing landscape involves state regulators, testing laboratories, cultivators, patient advocacy groups, and medical professionals, each with distinct priorities and perspectives on appropriate safety standards.

State Regulatory Agencies

State cannabis control boards face the challenge of balancing patient safety, industry viability, and limited regulatory resources. The California Department of Cannabis Control, Massachusetts Cannabis Control Commission, and similar agencies in other states develop testing rules, license laboratories, and enforce compliance. These agencies often lack the toxicology expertise and research budgets available to federal counterparts like the FDA. Regulators must weigh industry lobbying for relaxed standards against patient advocate demands for pharmaceutical-grade safety.

Testing Laboratories

Licensed cannabis testing laboratories conduct the microbial analyses that determine whether products reach consumers. Major laboratory operators include SC Labs (California), MCR Labs (Massachusetts), and Steep Hill (multi-state). These laboratories invested millions in equipment, method validation, and accreditation. They face pressure to deliver fast turnaround times while maintaining accuracy. Some laboratories have faced license suspensions for failing proficiency tests or allegedly manipulating results to favor clients. The integrity of testing depends on robust laboratory oversight and proficiency testing programs.

Cultivators and Processors

Cannabis cultivators bear the financial risk of failed batches. Large multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries have resources to implement comprehensive environmental controls, staff microbiologists, and absorb occasional crop losses. Small craft cultivators operate on thin margins where a single failed harvest can mean bankruptcy. Industry trade groups including the National Cannabis Industry Association and state-level associations lobby for remediation pathways, statistical sampling rather than batch testing, and higher action levels for total yeast and mold.

Patient Advocacy Organizations

Groups representing medical cannabis patients, particularly immunocompromised populations, advocate for stringent testing standards. Americans for Safe Access has consistently pushed for species-specific Aspergillus testing and zero-tolerance policies. These organizations argue that medical cannabis should meet pharmaceutical safety standards, not agricultural commodity standards. Patient advocates oppose remediation, contending that products initially contaminated should never reach vulnerable patients regardless of subsequent treatment.

Medical and Public Health Professionals

Pulmonologists, infectious disease specialists, and public health researchers provide the scientific foundation for testing policies. The American Thoracic Society has published guidance on fungal infections in cannabis users. Individual physicians treating immunocompromised patients often advise against inhaled cannabis due to contamination concerns, recommending edibles or tinctures instead. Public health departments in states with legal cannabis programs monitor adverse event reports and conduct epidemiological surveillance, though systematic data remains limited.

Legal and Regulatory Framework

Cannabis mold testing exists in a federal legal vacuum, governed entirely by state law and regulation without FDA oversight, creating jurisdictional conflicts and limiting interstate standardization. The Controlled Substances Act (21 U.S.C. § 812) classifies cannabis as a Schedule I substance, prohibiting FDA from regulating it as a food, drug, or dietary supplement. This federal prohibition forces states to develop independent regulatory frameworks without access to federal public health resources or interstate commerce mechanisms that could promote standardization. State cannabis laws typically authorize regulatory agencies to establish testing requirements through administrative rulemaking. California's Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) directed the Department of Cannabis Control to adopt testing standards. Massachusetts General Laws Chapter 94G authorized the Cannabis Control Commission to require testing. These enabling statutes provide broad authority but limited specific guidance, leaving technical details to regulatory agencies. Administrative Procedure Acts in each state govern how testing rules are adopted, typically requiring public comment periods, economic impact analyses, and legislative oversight. Industry stakeholders use these processes to influence testing standards, submitting comments and data during rulemaking. State cannabis regulations have the force of law and are enforceable through license sanctions, fines, and criminal penalties for violations. However, enforcement capacity varies widely. Well-funded programs in California and Massachusetts conduct regular compliance inspections and laboratory audits. Smaller state programs struggle with limited inspector staff and technical expertise. No federal court has addressed whether state cannabis testing requirements conflict with federal law, though the Rohrabacher-Farr Amendment (renewed annually in federal appropriations bills) prohibits the Department of Justice from interfering with state medical cannabis programs. This provides some legal protection for state regulatory frameworks. The lack of interstate commerce in cannabis prevents federal jurisdiction under the Commerce Clause. Each state operates a closed-loop system where cannabis cannot cross state lines, even between legal states. This fragmentation perpetuates testing inconsistencies and prevents economies of scale in laboratory services.

Market and Business Implications

Mold testing requirements impose significant costs on cannabis operators, influence cultivation practices and product pricing, and create competitive advantages for well-capitalized companies that can implement advanced contamination controls. Testing costs represent a direct expense for every batch brought to market. At $200 to $400 per microbial test, a cultivator producing 100 pounds per month across multiple strains may spend $5,000 to $10,000 monthly on testing alone. These costs are passed through the supply chain, contributing to retail prices that remain higher than illicit market alternatives in many jurisdictions. Failed batches create catastrophic losses. A 50-pound harvest worth $75,000 wholesale becomes worthless if it fails microbial testing in a state prohibiting remediation. Even where remediation is permitted, converting flower to concentrate reduces value and requires additional processing costs. Industry surveys suggest 5 to 15 percent of harvests fail testing in mature markets, representing hundreds of millions in annual losses across the sector. Testing requirements drive capital investment in environmental controls. Cultivators install HEPA filtration, implement positive pressure systems, monitor humidity continuously, and train staff in aseptic techniques. These investments favor large operators with access to capital. Multi-state operators standardize cultivation protocols across facilities, achieving consistency that reduces failure rates. Small craft cultivators often lack resources for sophisticated environmental controls, facing higher failure rates and greater financial risk. The testing infrastructure itself represents a significant market. Licensed laboratories generated an estimated $200 million in testing revenue across legal states in 2025. Laboratory equipment manufacturers, including companies supplying qPCR systems and automated plating equipment, benefit from mandatory testing. Proficiency testing providers and laboratory accreditation bodies (such as ISO 17025 accreditors) serve the cannabis testing sector. Insurance markets have developed around testing risk. Some cultivators purchase crop insurance that covers losses from failed testing, though premiums are high and coverage limitations significant. Testing laboratories carry errors and omissions insurance to protect against liability from inaccurate results. Remediation services emerged as a business opportunity in states permitting treatment of failed batches. Companies offering ozone treatment, irradiation, and extraction services charge fees to salvage contaminated cannabis. The remediation sector remains controversial, with patient advocates questioning whether these services prioritize profit over safety. Testing requirements influence product mix. Concentrates and edibles face lower contamination risk than flower because extraction and cooking processes kill most microorganisms. Some operators shifted toward concentrate production to reduce testing failures. This market evolution affects consumer access to traditional flower products, particularly for medical patients who prefer inhalation. Vertical integration provides competitive advantages in managing testing risk. Companies controlling cultivation, processing, and retail can absorb failed batches into concentrate production without selling to third parties, minimizing financial impact. This dynamic accelerates industry consolidation as small operators struggle with testing compliance costs.

What Experts Say About Current Testing Standards

Scientific and medical experts express concern that current cannabis mold testing standards lag behind pharmaceutical safety protocols and may inadequately protect immunocompromised patients, while industry experts emphasize the need for risk-based approaches that balance safety and economic viability. Dr. Donald Land, a laboratory director who has worked extensively in cannabis testing, has stated in published interviews that species-specific Aspergillus testing using validated methods is essential for medical cannabis programs. According to Land, total yeast and mold counts provide limited safety information because they do not distinguish between benign organisms and dangerous pathogens. He has advocated for qPCR methods combined with culture confirmation to provide both rapid results and species identification. Infectious disease specialists treating immunocompromised patients emphasize the serious risks of Aspergillus exposure. Research published in Clinical Infectious Diseases documented cases of invasive aspergillosis in cannabis users with weakened immune systems. Medical professionals treating these populations often recommend against inhaled cannabis entirely, advising patients to use edibles or tinctures to avoid respiratory exposure to any fungal material. Mycologists studying cannabis contamination have identified limitations in current testing approaches. Dr. Kevin McKernan, a genomics researcher, has noted that DNA-based testing methods detect genetic material from dead organisms, potentially overstating contamination levels. According to McKernan's published research, culture-based methods provide more accurate assessment of viable organism counts but require longer turnaround times that disrupt supply chains. Patient safety advocates argue that cannabis marketed as medicine should meet United States Pharmacopeia standards applied to pharmaceutical products. According to statements from Americans for Safe Access, current state testing requirements fall short of these standards, particularly regarding mycotoxin testing and environmental monitoring of cultivation facilities. These advocates contend that zero-tolerance policies for pathogenic organisms are appropriate for products consumed by vulnerable patients. Industry consultants emphasize the need for risk-based approaches that consider consumption method and patient population. According to this perspective, flower intended for inhalation by immunocompromised medical patients warrants the most stringent testing, while edibles that undergo cooking processes present lower risk. Some industry experts have proposed tiered testing requirements based on product type and intended use. Laboratory quality experts stress the importance of proficiency testing and accreditation. According to the AOAC Cannabis Analytical Science Program, laboratories must participate in regular proficiency testing to ensure accuracy and consistency. Proficiency testing involves analyzing blind samples with known contamination levels to verify laboratory performance. States with robust proficiency testing programs identify and remediate laboratory performance issues before inaccurate results reach the market. Regulatory officials acknowledge the challenges of developing testing standards without federal guidance. According to statements from the Cannabis Regulators Association, state agencies must balance scientific evidence, stakeholder input, and practical implementation constraints. Regulators note that overly stringent requirements may drive consumers to untested black market products, while inadequate standards fail to protect public health.

What's Next for Cannabis Mold Testing

Cannabis mold testing standards are likely to evolve toward greater stringency and standardization over the next 3 to 5 years, driven by patient safety concerns, potential federal rescheduling, and industry maturation, though significant interstate variation will persist absent federal oversight. The May 2026 Cannabis Wire article questioning testing adequacy reflects growing scrutiny of current standards. Patient advocacy organizations are expected to intensify pressure on state regulators to adopt species-specific Aspergillus testing, lower action levels for total yeast and mold, and mandatory mycotoxin testing. Several states are conducting regulatory reviews that may result in strengthened requirements by 2027. Federal rescheduling of cannabis from Schedule I to Schedule III, proposed by the Department of Health and Human Services in 2023 and under review by the Drug Enforcement Administration, could transform the testing landscape. If cannabis moves to Schedule III, FDA jurisdiction may expand, potentially establishing national testing standards. However, the rescheduling process remains pending as of May 2026, with no definitive timeline for DEA action. Technological advances in testing methodology may improve both speed and accuracy. Next-generation sequencing technologies can identify a broad range of fungal species in a single test, providing comprehensive contamination profiles. Portable testing devices under development could enable on-site screening, reducing turnaround times and costs. However, these technologies require extensive validation before regulatory acceptance. Industry consolidation is likely to continue, with well-capitalized operators implementing pharmaceutical-grade cultivation controls that minimize contamination risk. This professionalization may reduce overall failure rates and support more stringent testing standards as the industry demonstrates capability to meet higher benchmarks. Interstate compacts for cannabis commerce, if they emerge, would create pressure for testing harmonization. The concept of allowing cannabis to cross state lines between legal jurisdictions has gained attention, but would require consistent safety standards to function. Such compacts remain speculative as of 2026. Research into health outcomes associated with cannabis mold exposure remains limited but is expanding. Academic institutions in states with legal cannabis are conducting epidemiological studies tracking adverse events. This research may provide the evidence base for more refined risk assessments and targeted testing requirements. The remediation debate will likely continue. Patient advocates will push to prohibit remediation of products intended for medical use, while industry groups will seek to expand remediation pathways to reduce waste. States may move toward tiered systems where medical products face stricter standards than adult-use products. Mycotoxin testing may become more widespread. While some states test for aflatoxins produced by Aspergillus flavus, comprehensive mycotoxin panels are not yet standard. As testing technology improves and costs decline, regulators may add mycotoxin requirements to address the concern that killing mold organisms does not eliminate toxic metabolites. Laboratory oversight is expected to strengthen. States are implementing more rigorous proficiency testing programs, increasing inspection frequency, and pursuing enforcement actions against laboratories that fail to meet performance standards. This oversight is essential to maintaining testing integrity as financial pressures create incentives for laboratories to favor clients. The calendar for near-term regulatory action includes several key dates. California's Department of Cannabis Control is conducting a comprehensive regulatory review with proposed rule changes expected by December 2026. Massachusetts is evaluating its prohibition on flower remediation, with a decision anticipated in 2027. The DEA's final decision on cannabis rescheduling, whenever it occurs, will trigger a cascade of regulatory adjustments across state programs.

Further Reading and Primary Sources

• California Code of Regulations Title 16, Division 42 (Cannabis Testing Laboratories) - https://govt.westlaw.com/calregs/Browse/Home/California/CaliforniaCodeofRegulations
• Massachusetts Cannabis Control Commission Regulations (935 CMR 500.000) - https://mass-cannabis-control.com/regulations/
• AOAC Official Method 2020.04 (Detection of Aspergillus in Cannabis) - https://www.aoac.org/official-methods-of-analysis/
• Americans for Safe Access: Medical Cannabis Quality Standards - https://www.safeaccessnow.org/
• Cannabis Regulators Association: Testing Standards Working Group - https://cannabisregulators.org/
• Clinical Infectious Diseases: Aspergillosis Associated with Cannabis Use - https://academic.oup.com/cid
• National Cannabis Industry Association: Testing and Quality Assurance Resources - https://thecannabisindustry.org/
• U.S. Controlled Substances Act (21 U.S.C. § 812) - https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm
• Colorado Marijuana Enforcement Division: Testing Requirements - https://sbg.colorado.gov/med
• Michigan Marijuana Regulatory Agency: Testing Rules - https://www.michigan.gov/mra